Company intelligence / Profile preview

CPTx

Planegg/Munich, Bavaria, Germanycptx.bio ↗

Ownership: Private
Development stage: Preclinical

Overview

CPTx has demonstrated the ability to synthesize large-scale single-stranded DNA constructs with high precision. Their proprietary nonviral gene carrier system shows promise in overcoming immunogenicity and targeting challenges seen with traditional gene therapies. Lead programs include a pan-influenza antiviral candidate and an in vivo CAR-T therapy approaching IND-enabling studies; no human clinical data reported yet as of May 2025[3][5].

Therapeutic areas: OncologyRare DiseasesImmunologyInfectious Diseases
Modalities: Single-stranded DNA therapeuticsIn vivo CAR-T cell therapyGene nanocarriers (nonviral, non-LNP)Multivalent drug display using DNA nanostructuresSmall molecules, peptides, proteins & antibodies (as payloads via their platform)[7]
Industry: Biotech

Drug pipeline

1 asset

ssDNA-tLNP CAR T

Preclinical

Partnerships

Not specifically named; two partnership assets mentioned but partners undisclosed as of May 2025[3]. Investors include Bayern Kapital among others.

Beyond the preview

Go deeper on CPTx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CPTx.

Explore the full profile